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Background. Detection of pneumococcus by lytA polymerase chain reaction (PCR) in blood had poor diagnostic accuracy for 
diagnosing pneumococcal pneumonia in children in 9 African and Asian sites. We assessed the value of blood lytA quantification in 
diagnosing pneumococcal pneumonia.
Methods. The Pneumonia Etiology Research for Child Health (PERCH) case-control study tested whole blood by PCR for 
pneumococcus in children aged 1–59 months hospitalized with signs of pneumonia and in age–frequency matched community con-
trols. The distribution of load among PCR-positive participants was compared between microbiologically confirmed pneumococcal 
pneumonia (MCPP) cases, cases confirmed for nonpneumococcal pathogens, nonconfirmed cases, and controls. Receiver operating 
characteristic analyses determined the “optimal threshold” that distinguished MCPP cases from controls.
Results. Load was available for 290 of 291 cases with pneumococcal PCR detected in blood and 273 of 273 controls. Load was 
higher in MCPP cases than controls (median, 4.0 × 103 vs 0.19 × 103 copies/mL), but overlapped substantially (range, 0.16–989.9 × 103 
copies/mL and 0.01–551.9 × 103 copies/mL, respectively). The proportion with high load (≥2.2 log10 copies/mL) was 62.5% among 
MCPP cases, 4.3% among nonconfirmed cases, 9.3% among cases confirmed for a nonpneumococcal pathogen, and 3.1% among 
controls. Pneumococcal load in blood was not associated with respiratory tract illness in controls (P = .32). High blood pneumococcal 
load was associated with alveolar consolidation on chest radiograph in nonconfirmed cases, and with high (>6.9 log10 copies/mL) 
nasopharyngeal/oropharyngeal load and C-reactive protein ≥40 mg/L (both P < .01) in nonconfirmed cases but not controls.
Conclusions. Quantitative pneumococcal PCR in blood has limited diagnostic utility for identifying pneumococcal pneumonia 
in individual children, but may be informative in epidemiological studies.
Keywords. pneumonia; pneumococcus; PCR; blood; diagnosis.
 
The conventional method to identify the cause of pediatric bac-
terial pneumonia is by blood culture, but this has low sensitivity 
(<10%) to detect pneumococcal pneumonia, a leading bacte-
rial cause of pneumonia [1, 2]. Detection of pneumococcus in 
blood by polymerase chain reaction (PCR) may be more sen-
sitive for detecting bloodstream infection, especially in cases 
treated with antibiotics prior to specimen collection [2]. If so, 
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this test could identify blood culture–negative pneumococcal 
pneumonia cases.
However, when blood pneumococcal PCR was evaluated in 
the Pneumonia Etiology Research for Child Health (PERCH) 
study, we found that whole-blood lytA positivity had poor diag-
nostic accuracy, in terms of both sensitivity and specificity [3]. 
Others have observed that higher pneumococcal PCR load in 
the blood is associated with greater severity of disease [4–7], so 
it is possible that the load of pneumococcus in blood is higher 
in children with pneumonia than in well children. We evaluated 
the utility of quantitative whole-blood pneumococcal PCR as 




As described and presented elsewhere [8, 9], PERCH is a 
case-control study evaluating the etiology of severe and very 
severe pneumonia conducted in 9 sites in 5 African and 2 
Asian countries: Basse, The Gambia; Bamako, Mali; Kilifi, 
Kenya; Soweto, South Africa; Lusaka, Zambia; Nakhon 
Phanom and Sa Kaeo, Thailand; and Dhaka and Matlab, 
Bangladesh. Enrollment occurred for 24 consecutive months at 
each site during August 2011–January 2014. Cases were chil-
dren aged 1–59 months hospitalized with 2005 World Health 
Organization (WHO)–defined severe or very severe pneumo-
nia. Controls were selected randomly from the community and 
were frequency-matched to cases for age (1 to <6 months, 6 to 
<12 months, 12 to <24 months, and 24–59 months) and month 
of enrollment. Controls were also matched on human immu-
nodeficiency virus (HIV) status at the 2 sites with high HIV 
prevalence (South Africa and Zambia).
Cases and controls were evaluated at enrollment for clini-
cal signs and symptoms as well as risk factors for pneumonia. 
Severe pneumonia was defined as having cough or difficulty 
breathing and lower chest wall in-drawing that, in the sub-
set of children presenting with wheeze, did not resolve after 
administration of bronchodilators; very severe pneumonia was 
defined as having cough or difficulty breathing and at least 1 of 
the following: central cyanosis, difficulty breastfeeding/drink-
ing, vomiting everything, multiple or prolonged convulsions, 
lethargy, unconsciousness, or head nodding. Controls were 
enrolled regardless of presence of respiratory symptoms, as 
long as they did not have case-defining severe or very severe 
pneumonia. Chest radiographs (CXRs) performed at the time 
of admission were defined as CXR-positive (CXR+) if they were 
classified as either alveolar consolidation or other infiltrates 
using WHO methods [10, 11]. Respiratory tract illness (RTI) 
in controls was defined as having cough or runny nose. RTI was 
also defined as having (1) at least 1 of ear discharge, wheezing, 
or difficulty breathing and (2) either a measured fever (temper-
ature ≥38.0°C) within the previous 48 hours or a history of sore 
throat. Prior antibiotic exposure was defined as either a positive 
serum bioassay (cases and controls) or documentation of anti-
biotics administered at the referral or study hospital prior to 
specimen collection (cases only) [2].
Pneumococcal conjugate vaccine (PCV) was introduced 
prior to PERCH in The Gambia, Kenya, Mali, and South Africa. 
PCV was introduced in July 2013 in Zambia, 18 months after 
enrollment started. In Bangladesh and Thailand, PCV was 
available but only in the private market, with almost no usage 
reported in the study areas.
All specimen collection and laboratory methods were stand-
ardized across all sites and have been described elsewhere [12]. 
Pleural fluid was collected from cases when clinically indi-
cated at all sites, and lung aspirates were collected at select sites 
(The Gambia, South Africa, Mali, and Bangladesh) when rele-
vant and feasible. At all sites, nasopharyngeal and oropharyn-
geal (NP/OP) swabs were obtained and combined, and whole 
blood was collected, from both cases and controls at the time of 
enrollment. Blood, lung aspirates, and pleural fluid from cases 
were cultured for detection of bacterial organisms. NP/OP, lung 
aspirate, and pleural fluid specimens were tested for 33 patho-
gens including pneumococcus using the Fast-track Diagnostics 
Respiratory Pathogens 33 test (Fast-track Diagnostics [FTD], 
Sliema, Malta). Quantification data were generated through 
creation of standard curves using 10-fold serial dilutions of 
plasmid standards, with calculation of pathogen load (copies/
mL) from the sample cycle threshold values. High PCR load in 
NP/OP specimens was defined as >6.9 log10 copies/mL, which 
was the optimal colonization load threshold for discriminat-
ing microbiologically confirmed pneumococcal pneumonia 
(MCPP) cases from all controls [13].
Whole-blood specimens from cases and controls were eval-
uated for the presence of the Streptococcus pneumoniae autoly-
sin gene lytA using a quantitative real-time PCR assay based on 
the US Centers for Disease Control and Prevention method, as 
described previously [3, 14]. Quantification standards consist-
ing of lytA plasmids (FTD) diluted 1:10 from 107 copies/mL to 
102 copies/mL were run in triplicate on every plate. Data points 
with detected pneumococcal concentration below the lower 
limit of linearity and lower limit of detection of the assay were 
retained in the data set, with the understanding that accuracy 
and precision are affected in that range.
Cases were defined as MCPP if they had pneumococcus 
detected by culture of blood, lung aspirate, or pleural fluid, PCR 
of lung aspirate or pleural fluid, or detection of pneumococcal 
antigen (BinaxNOW, Alere, Orlando, Florida) in pleural fluid. 
Cases were defined as “confirmed for a nonpneumococcal path-
ogen” if they were not MCPP cases but were culture positive 
(blood, lung aspirate, or pleural fluid) or PCR positive in lung 
aspirate or pleural fluid for nonpneumococcal pathogenic bac-
teria. Nonconfirmed cases had no bacterial pathogens detected 
by culture of blood, lung aspirate, or pleural fluid, PCR of lung 
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aspirate or pleural fluid, or detection of pneumococcal antigen 
on pleural fluid.
Analysis
Median blood pneumococcal load was compared between 
groups using the Kruskal-Wallis test. The optimal threshold for 
discriminating all MCPP cases from all controls (ie, including 
the blood pneumococcal PCR-negative children) was identified 
with receiver operating characteristic (ROC) analyses using the 
Youden index to maximize sensitivity and specificity [15]. To 
guard against bias in the estimates of sensitivity due to having a 
small number of MCPP cases, the Youden index was calculated 
using leave-one-out cross-validation [16]. The proportion with 
high load, defined as those above the threshold, was determined 
for cases stratified by bacteremia status, MCPP, and CXR find-
ings, and for controls by RTI status. Analyses were performed 
overall and stratified by site, HIV status, and prior antibiotic 
exposure. Comparisons of proportions were made using the χ2 
test or Fisher exact test.
Ethical Considerations
The PERCH study protocol was approved by the institutional 
review board or ethical review committee at each of the study 
site institutions and at the Johns Hopkins Bloomberg School of 
Table 1. Median Pneumococcal Polymerase Chain Reaction (PCR) Load (103 Copies/mL) in Whole Blood Among Children Who Were Whole-Blood PCR 
Positive, by Case/Control Group and Characteristic
Characteristic
































Overall 36 4.1f (1.1–77.4) 242 0.29f (0.14–0.93) 127 0.30f (0.14–1.0) 12 1.6f (0.32–5.7) 273 0.19f (0.11–0.48)
PERCH sites P = .51 P < .001 P = .31 P = .41 P < .01
 Kenya 3 83.9 (4.6–419.8) 25 0.17 (0.14–0.37) 15 0.23 (0.12–0.48) 3 0.21 (0.06–1.5) 48 0.24 (0.12–0.45)
 The Gambia 6 2.2 (0.63–8.8) 51 0.21 (0.11–0.52) 20 0.24 (0.10–0.46) 4 2.6 (1.1–7.5) 47 0.23 (0.13–0.52)
 Mali 19 2.4 (0.53–96.8) 56 0.59 (0.21–3.1) 25 0.53 (0.17–2.1) 2 43.2 (0.11–86.2) 38 0.40 (0.08–1.1)
 Zambia 4 40.0 (4.1–98.9) 37 0.30 (0.14–1.2) 22 0.30 (0.15–1.4) 2 1.6 (0.43–2.8) 31 0.17 (0.11–0.38)
 South Africa 4 4.8 (1.9–20.6) 66 0.27 (0.16–0.93) 44 0.30 (0.16–0.94) 1 7.8 (7.8–7.8) 98 0.16 (0.09–0.34)
 Bangladesh 0 … 5 0.09 (0.06–0.30) 1 25.1 (25.1–25.1) 0 … 6 0.10 (0.06–0.10)
 Thailand 0 … 2 0.05 (0.01–0.09) 0 … 0 … 5 0.27 (0.06–0.86)
Age P = .27 P = .57 P = .71 P = .35 P = .71
 1–5 mo 7 144.6 (1.2–731.6) 96 0.25 (0.15–0.53) 51 0.30 (0.17–0.53) 3 0.43 (0.06–1.5) 88 0.19 (0.11–0.49)
 6–11 mo 10 2.4 (1.1–4.2) 68 0.32 (0.14–1.2) 33 0.30 (0.13–0.93) 3 2.8 (0.21–86.2) 72 0.20 (0.10–0.41)
 12–23 mo 9 7.1 (1.8–12.1) 52 0.27 (0.13–1.4) 32 0.30 (0.13–1.6) 3 0.49 (0.11–11.4) 64 0.17 (0.11–0.33)
 24–59 mo 10 2.1 (0.53–7.7) 26 0.31 (0.13–3.8) 11 1.3 (0.12–17.0) 3 3.6 (1.7–7.8) 49 0.19 (0.11–0.88)
HIV infected P = .68 P = .27 P = .16 P = .12 P = .96
 Yesg 10 3.9 (0.53–12.1) 24 0.32 (0.17–21.3) 19 0.47 (0.29–25.6) 3 7.8 (2.8–86.2) 19 0.16 (0.11–0.46)
 No 23 2.8 (1.2–83.9) 197 0.27 (0.14–0.93) 98 0.28 (0.14–0.93) 8 1.0 (0.27–2.6) 224 0.19 (0.11–0.46)
Prior antibioticsh P = .25 P = .21 P = .03 P = .47 P = .49
 Yes 9 3.9 (1.9–126.8) 100 0.30 (0.15–1.1) 64 0.39 (0.18–1.5) 5 0.43 (0.11–3.6) 9 0.23 (0.19–0.61)
 No 25 2.4 (0.73–12.1) 131 0.28 (0.12–0.86) 58 0.22 (0.12–0.86) 6 1.6 (0.49–7.8) 253 0.19 (0.11–0.47)
Pneumococcal NP/OP 
PCR load >6.9 log10 
copies/mL
P = .97 P = .03 P = .05 P = .10 P = .19
 Yes 26 4.1 (0.73–96.8) 48 0.46 (0.16–5.1) 33 0.50 (0.16–13.1) 3 7.8 (1.5–86.2) 27 0.28 (0.13–0.88)
 No 9 4.6 (1.5–33.6) 191 0.28 (0.14–0.67) 92 0.30 (0.14–0.69) 8 0.46 (0.16–3.2) 243 0.18 (0.11–0.45)
All P values obtained by Kruskal-Wallis test; P values within cells represent comparison within the case/control group for that characteristic. Bold indicates P < .05.
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; MCPP, microbiologically confirmed pneumococcal pneumonia; NP/OP, nasopharyngeal/oropharyngeal; PCR+, 
polymerase chain reaction positive for lytA gene; PERCH, Pneumonia Etiology Research for Child Health.
aMCPP defined as pneumococcus isolated from culture of blood, lung aspirate, pleural fluid, PCR of lung aspirate or pleural fluid, or detection of Streptococcus pneumoniae antigen in 
pleural fluid specimens on BinaxNOW.
bNonconfirmed cases defined as cases without isolation of bacteria from culture of blood, lung aspirate or pleural fluid, or PCR of lung aspirate or pleural fluid.
cCXR positive (CXR+) defined as radiographic evidence of pneumonia (consolidation and/or other infiltrates).
dConfirmed nonpneumococcal bacterial case was defined as a case with any nonpneumococcal bacterial pathogen detected by blood culture, by lung aspirate culture or PCR, or by pleural 
fluid culture or PCR.
eMedian load = median whole-blood lytA load (103 copies/mL) among children with PCR-positive whole-blood specimens.
fP value for MCPP vs nonconfirmed, all controls, and nonconfirmed CXR+ cases, <.001 for all; P value for MCPP vs confirmed non-pneumococcal cases, .06; P value for nonconfirmed 
cases vs confirmed non-pneumococcal cases, .05; P value for confirmed non-pneumococcal vs all controls, .003; P value for nonconfirmed cases vs all controls, <.001.
gControls were matched on HIV status at the 2 sites with high HIV prevalence (South Africa and Zambia).
hPrior antibiotics defined as serum bioassay positive (cases and controls), antibiotic administration at the referral facility, or antibiotic administration prior to whole-blood specimen collec-
tion at the study facility (cases only).
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Public Health. Parents or guardians of all participants provided 
written informed consent.
RESULTS
Whole-Blood Pneumococcal PCR Load Distribution
Blood was tested for pneumococcus by PCR in 3995 (94.4%) 
cases and 4987 (93.7%) community controls. Pneumococcal 
load was evaluated in all children who were blood pneumo-
coccal PCR positive, including 290 (7.3%) cases (36 MCPP 
cases, 242 nonconfirmed cases, and 12 cases confirmed for 
a nonpneumococcal pathogen) and 273 (5.5%) controls; 1 
case who was pneumococcal PCR positive was missing load 
data. MCPP cases were identified only at the African sites 
(range, n = 3–19 MCPP cases who were blood PCR positive; 
Table 1).
Blood pneumococcal PCR load was higher among MCPP 
cases (median,  4.0  ×  103 copies/mL) compared with con-
trols (median, 0.19 ×  103copies/mL; P <  .001; Table 1), but 
some MCPP cases had low load (range, 0.16–989.9  ×  103 
copies/mL) and some controls had high load (range, 0.01–
551.9  ×  103 copies/mL; Figure  1A and Supplementary 
Figure  1). Load among MCPP cases was also higher than 
among nonconfirmed cases (median, 0.29 × 103 copies/mL; 
P  <  .001). Interestingly, load among cases confirmed for 
nonpneumococcal pathogens (median, 1.6 × 103 copies/mL; 
Table 1 and Supplementary Table 1) was also higher than that 
among nonconfirmed cases (P = .05) and controls (P = .003). 
Median load was similar in controls with and without RTI 
(Supplementary Table 2).
Whole-Blood Pneumococcal PCR Load Threshold
ROC analyses determined that ≥2.2 log10 copies/mL was the 
optimal threshold that maximized sensitivity and specificity 
to distinguish MCPP cases from controls (Figure  1B); 62.5% 
of MCPP cases were above the threshold vs 3.1% of controls 
(Figure 2A). The threshold was similar when restricted to HIV-
negative children and when determined using controls without 
RTI (data not shown).
When evaluating all cases and controls as opposed to just 
those who were positive by blood PCR, the proportion of chil-
dren who were positive but had low blood load (ie, <2.2 log10 
copies/mL) was similar regardless of case or control group 
(range, 1.8%–2.4%; Figure 2A). However, among those positive 
by blood PCR, the proportion of children with high pneumo-
coccal load differed by case and control group. Only 1 (2.8%) 
MCPP case with pneumococcus detected in blood by PCR 
had low load; thus, the impact of the threshold on sensitivity 
(62.5%) was minimal. However, 56% (154/273) of PCR-positive 
controls had high blood pneumococcal load (3.1% of all con-
trols); using the threshold improved specificity to detect MCPP 
cases by 2.4% (to 96.9%) over that of any PCR positivity. The 
proportion of RTI controls with high load (3.6%) was not 
statistically greater than that of non-RTI controls (2.9%; P = .21; 
Supplementary Table  4A). Among 12 blood pneumococcal 
PCR–positive cases confirmed for a nonpneumococcal etiology, 
10 (83.3%) had high load (Figure 2A). Of these 10 cases, pneu-
mococcus was detected in the nasopharynx by culture in 4 and 
by PCR in all 9 of those with results (Supplementary Table 1). 
There was a wide diversity among the organisms cultured 
from blood in this group, some of which have previously been 
observed in coinfections with pneumococcus [17]. Two cul-
tures revealed Haemophilus influenzae, and the remaining were 
Candida species, which is not thought to cause pneumonia; 
Acinetobacter species, which can cause pneumonia but is also a 
common skin contaminant; Neisseria meningitidis; Escherichia 
coli; Pseudomonas aeruginosa; Staphylococcus aureus; and 
Salmonella species plus Streptococcus pyogenes.
Figure  1. Comparison of pneumococcal polymerase chain reaction (PCR)a load 
in whole blood between microbiologically confirmed pneumococcal pneumonia 
(MCPP)b cases and community controls. A, load distribution among PCR-positive 
children. B, Receiver operating characteristic analysis among all children, including 
PCR-negative children. aPneumococcal load (density) by PCR for the lytA gene (log10 
copies/mL) in whole-blood specimens. bMCPP defined as pneumococcus detected 
by culture of blood, lung aspirate, or pleural fluid, PCR of lung aspirate or pleural 
fluid, or BinaxNOW of pleural fluid.
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Among nonconfirmed cases who were pneumococcal 
PCR positive in blood, 68.3% had high load (71.7% of CXR+-
nonconfirmed cases), resulting in 4.3% and 5.2% of all noncon-
firmed cases and CXR+-nonconfirmed cases, respectively, with 
high load (Figure 2A). Although the percentage of nonconfirmed 
cases with high load was greater than that of controls (4.3% vs 
3.1%; unadjusted P < .01), the association was not strong (odds 
ratio adjusted for site [AOR], 1.3; 95% confidence interval [CI], 
1.0–1.6). Because of this, and in an effort to increase specificity, 
we evaluated whether a higher threshold could identify whether 
some of the 166 individual nonconfirmed cases that were above 
the 2.2 log10 copies/mL threshold had a higher likelihood of hav-
ing pneumococcal pneumonia than others. A threshold of >3.5 
log10 copies/mL that visually distinguished MCPP cases from 
controls among PCR-positive children was evaluated (Figure 
1A). Sensitivity among HIV-uninfected MCPP cases was greatly 
diminished (32.6%) and positivity in all other groups, including 
nonconfirmed cases, was ≤2% (Table 2). Although the ability to 
distinguish nonconfirmed cases from controls was improved 
(AOR, 2.7; 95% CI, 1.4–5.3), only n = 30 (0.8%) nonconfirmed 
cases had load >3.5 log10 copies/mL, reducing the value of a 
higher threshold to identify hidden pneumococcal pneumonia 
cases.
There was some variation by site of the performance of high 
blood pneumococcal load to detect MCPP cases, although num-
bers were too small to detect any statistical significance (Figure 2B). 
Pneumococcal blood load varied significantly among the sites 
for both nonconfirmed cases and controls, with Mali having the 
highest load (median, 0.59 and 0.40 × 103 copies/mL for noncon-
firmed cases and controls, respectively) and Bangladesh the low-
est (median, 0.09 and 0.1 × 103copies/mL, respectively; Table 1). 
However, data for the 2 Asian countries are limited because of the 
extremely small numbers (n = 3–7) of pneumococcal PCR–posi-
tive nonconfirmed cases and controls. The proportion of noncon-
firmed cases with high load ranged in African sites from 2.3% in 
Kenya to 7.6% in Mali (P < .001; Figure 2B).
Figure 2. Percentage of children with whole-blood pneumococcal polymerase chain reaction (PCR) load >2.2 log10 copies/mL by case/control group overall (A) and by site 
(B). Denominator numbers for (B) are provided in Supplementary Table 5. Abbreviations: BCx+, blood culture positive; Conf non-Spn, a case with any nonpneumococcal bacte-
rial pathogen detected by blood culture, by lung aspirate culture or PCR, or by pleural fluid culture or PCR; CXR+, findings of alveolar consolidation or other infiltrates on chest 
radiograph; CXR-AC, findings of alveolar consolidation (with or without other infiltrates) on chest radiograph; MCPP, microbiologically confirmed pneumococcal pneumonia 
(defined as pneumococcus isolated from culture of blood, lung aspirate, pleural fluid, PCR of lung aspirate or pleural fluid, or detection of Streptococcus pneumoniae antigen 
in pleural fluid on BinaxNOW); PCR+, polymerase chain reaction positive for lytA gene; RTI, respiratory tract illness.
Downloaded from https://academic.oup.com/cid/article-abstract/64/suppl_3/S357/3858231
by London School of Hygiene & Tropical Medicine user
on 26 January 2018
S362 • CID 2017:64 (suppl 3) • Deloria Knoll et al
Table 2. Characteristics Associated With Whole-Blood Pneumococcal Polymerase Chain Reaction Load in Human Immunodeficiency Virus–Uninfected 
Cases and Controls at All Sites
Characteristic
Pneumococcal Blood 














No. (%d) P Valuee No. (%) P Value No. (%) P Value No. (%)  P Value No. (%) P Value 
Total (column %d) 0 17 (39.5) 3402 (94.0) 1493 (93.3) 84 (90.3) 4525 (94.7)
<2.2 1 (2.3) 72 (2.0) 34 (2.1) 2 (2.2) 110 (2.3)
2.2–3.5 11 (25.6) 117 (3.2) 59 (3.7) 5 (5.4) 131 (2.7)
≥3.5 14 (32.6) 30 (0.8) 15 (0.9) 2 (2.2) 13 (0.3)
Female sex (row %d) 0 5 (29.4) .04 1420 (41.7) .61 649 (43.5) .47 49 (58.3) .74 2240 (49.5) .16
<2.2 0 (0.0) 25 (34.7) 12 (35.3) 1 (50.0) 65 (59.1)
2.2–3.5 4 (36.4) .08 50 (42.7) .60 30 (50.8) .30 4 (80.0) .63 69 (52.7) .39
≥3.5 10 (71.4) 11 (36.7) 7 (46.7) 0 (0.0) 7 (53.8)
At least 1 dose of PCVf 
(row %)
0 14 (82.4) .69 1730 (52.7) .002 788 (54.6) .09 37 (45.7) .33 2190 (49.6) <.001
<2.2 1 (100) 45 (64.3) 24 (72.7) 2 (100) 83 (77.6)
2.2–3.5 6 (60.0) .71 71 (64.0) >.99 33 (60.0) .53 2 (50.0) >.99 99 (78.6) >.99
≥3.5 11 (78.6) 19 (65.5) 10 (66.7)  1 (100) 10 (76.9)
Preceding antibioticsg 
(row %)
0 3 (17.6) .34 1283 (39.4) .91 581 (40.8) .04 39 (48.1) .63 78 (1.8) .05
<2.2 0 (0.0) 23 (34.3) 12 (36.4) 2 (100) 2 (1.9)
2.2–3.5 3 (27.3) .71 46 (40.7) .51 28 (50.0) .05 1 (20.0) .63 5 (3.9) .23
≥3.5 4 (33.3) 12 (41.4) 10 (66.7)  1 (50.0) 1 (7.7)
Pneumococcal NP/ 
OP PCR load >6.9 
log10 copies/mL (row 
%)
0 10 (62.5) .71 379 (11.3) <.001 175 (11.9) <.001 22 (26.8) .46 344 (7.8) .37
<2.2 0 (0.0) 11 (15.5) 8 (24.2) 0 (0.0) 10 (9.2)
2.2–3.5 8 (80.0) > .99 20 (17.4) .09 12 (20.7) .24 1 (25.0) > .99 13 (10.0) > .99
≥3.5 9 (64.3) 10 (33.3) 7 (46.7) 0 (0.0) 1 (7.7)
Very severe pneumonia 
(row %)
0 8 (47.1) .56 1064 (31.3) .04 423 (28.3) .018 37 (44.0) > .99 …
<2.2 1 (100) 23 (31.9) 9 (26.5) 2 (100) …
2.2–3.5 7 (63.6) .73 42 (35.9) 0.13 24 (40.7) .13 3 (60.0) .16 …
≥3.5 8 (57.1) 15 (50.0) 7 (46.7) 0 (0.0) …
CXR+ (row %) 0 14 (100) .02 1493 (51.2) .05 1493 (100) 41 (62.1) .59 …
<2.2 1 (100) 34 (50.0) 34 (100) 0 (0.0) …
2.2–3.5 7 (87.5) .40 59 (59.0) .14 59 (100) 3 (60.0) .52 …
≥3.5 7 (63.6) 15 (68.2) 15 (100)  2 (100) …
CXR with alveolar consol-
idation (row %)
0 11 (78.6) .13 678 (23.3) <.001 678 (45.4) <.001 28 (42.4) > .99 …
<2.2 1 (100) 16 (23.5) 16 (47.1) 0 (0.0) …
2.2–3.5 6 (75.0) .26 38 (38.0) <.001 38 (64.4) .003 2 (40.0) > .99 …
≥3.5 5 (45.5) 14 (63.6) 14 (93.3) 1 (50.0) …
Hypoxemia (row %) 0 4 (23.5) .23 1220 (35.9) .20 637 (42.7) .78 43 (51.8) .07 …
<2.2 0 (0.0) 19 (26.4) 13 (38.2) 1 (50.0) …
2.2–3.5 5 (45.5) > .99 54 (46.2) .11 28 (47.5) .77 1 (20.0) .61 …
≥3.5 6 (42.9) 11 (36.7) 4 (26.7) 0 (0.0) …
CRP ≥40 mg/L (row %) 0 12 (75) .23 726 (24.7) <.001 413 (31.8) <.001 53 (72.6) .79 …
<2.2 1 (100) 18 (29.0) 13 (41.9) 0 (0.0) …
2.2–3.5 8 (100) .58 38 (38.8) <.001 22 (44.0) .06 2 (100) > .99 …
≥3.5 9 (90.0) 17 (73.9) 10 (83.3)  1 (50.0) …
WBC count >15/mm3 
(row %)
0 9 (52.9) .48 1208 (37.2) .19 581 (40.9) .91 34 (42) .32 …
<2.2 1 (100) 25 (37.9) 12 (40.0) 0 (0.0) …
2.2–3.5 5 (50.0) .49 39 (35.1) .26 25 (44.6) .75 2 (40.0) > .99 …
≥3.5 5 (38.5) 6 (21.4) 4 (28.6)  0 (0.0) …
Died in hospital (row %) 0 3 (17.6) .34 174 (5.1) .03 70 (4.7) .09 24 (28.6) .85 …
<2.2 0 (0.0) 2 (2.8) 2 (5.9) 2 (100) …
2.2–3.5 2 (18.2) .45 10 (8.5) .05 3 (5.1) .26 2 (40.0) .16 …
≥3.5 5 (35.7) 4 (13.3) 3 (20.0)  0 (0.0) …
Table excludes human immunodeficiency virus (HIV)–infected children; children with unknown HIV status are included.
Abbreviations: CRP, C-reactive protein; CXR, chest radiograph; MCPP, microbiologically confirmed pneumococcal pneumonia; NP/OP, nasopharyngeal/oropharyngeal; PCR, polymerase chain 
reaction; PCV, pneumococcal conjugate vaccine; WBC, white blood cell; …, not applicable for controls.
aMCPP defined as pneumococcus isolated from culture of blood, lung aspirate, pleural fluid, PCR of lung aspirate or pleural fluid, or detection of Streptococcus pneumoniae antigen on 
BinaxNOW testing of pleural fluid.
bCXR positive (CXR+) defined as radiographic evidence of pneumonia (consolidation and/or other infiltrates).
cCase with any nonpneumococcal bacterial pathogen detected by blood culture, by lung aspirate culture or PCR, or by pleural fluid culture or PCR.
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Factors Associated With Whole-Blood Pneumococcal Load
Overall and by site, there were no notable associations between 
pneumococcal load and age, sex, HIV, or PCV use among those 
who were PCR positive (Tables 1 and 2 and Supplementary 
Table 3). Although the distribution of blood pneumococcal 
PCR load did not differ by receipt of antibiotics prior to sam-
ple collection among MCPP cases or controls, load was higher 
among nonconfirmed CXR+ cases if they had prior antibiot-
ics (median, 0.39 vs 0.22 × 103 copies/mL, P = .03; Table 1 and 
Supplementary Figure 2).
Children with high NP/OP loads were more likely to have 
higher loads in blood (Table  3 and Figure  3). Despite this, 
among nonconfirmed cases above the NP/OP threshold of >6.9 
log10 copies/mL, only 8.1% were above the blood threshold, and 
the majority (77.4%) of nonconfirmed cases above the blood 
threshold were below the NP/OP threshold.
Because associations between pneumococcal PCR load and 
pneumonia and pneumococcal risk factors may differ by HIV 
status, we restricted evaluations of factors associated with load 
distribution to HIV-negative children only in Table 2; how-
ever, associations above the threshold in Supplementary Table 
4A and 4B are shown for all children. Among nonconfirmed 
PCR positives, higher load was not associated with having very 
severe pneumonia, hypoxemia, CXR+, or white blood cell count 
>15/mm3, but there was a nonsignificant trend for proportion 
of children who died to increase with increasing load (Table 2). 
However, clinical measures considered suggestive of bacterial 
pneumonia were associated with increasing load, including 
findings of alveolar consolidation on CXR (23.5%, 38.0%, and 
63.6% for nonconfirmed cases with positive but <2.2, 2.2–3.5, 
and ≥3.5 log10 copies/mL, respectively) and C-reactive pro-
tein ≥40 mg/L (29.0%, 38.8%, and 73.9% for nonconfirmed 
cases with positive but <2.2, 2.2–3.5, and ≥3.5 log10 copies/mL, 
respectively; Table 2).
DISCUSSION
To our knowledge, the PERCH study is the only published eval-
uation of pneumococcal load as measured by lytA in blood to 
compare pneumonia patients with community controls, mostly 
because previous studies that evaluated healthy controls did 
not observe any controls to be pneumococcal PCR positive 
[18, 19]. We found that among children who had pneumococ-
cus in the blood as measured by PCR, median load was higher 
in children with MCPP than in community control children 
or children with pneumonia confirmed for a nonpneumococ-
cal organism. However, even though all but 1 pneumococcal 
PCR-positive MCPP case had high load (≥2.2 log10 copies/
mL), 37.5% of all MCPP cases did not because sensitivity for 
any positivity was low [3]. Additionally, many children with-
out evidence of pneumococcal pneumonia, including controls, 
had high load, demonstrating the poor specificity of blood load 
for use as a clinical diagnostic to identify specific cases with 
pneumococcal pneumonia. Of 273 community controls who 
were blood pneumococcal PCR positive, 56% had high load 
(3.1% overall). In addition, 10 of 12 (83.3%) PCR-positive cases 
confirmed for another etiology had high load (9.3% overall), 
which may mean either poor specificity or that pneumococcus 
was a coinfecting agent in these cases, just not cultured from 
blood. Despite this poor sensitivity and specificity, having high 
pneumococcal blood load may have some value in ascribing 
etiology in epidemiological studies as the overall proportion 
in controls (3.1%) was lower than that in nonconfirmed cases 
(4.3%), but the association was not strong (AOR, 1.3; 95% CI, 
1.0–1.6). Pneumococcal load among nonconfirmed cases was 
lower than among MCPP cases, suggesting that if PCR posi-
tives in nonconfirmed cases are pneumococcal cases, they are 
different from MCPP cases. Caution is needed in interpreting 
high load in pneumonia cases as having etiologies attributed to 
pneumococcus because of the relatively large proportion (9.3%) 
of cases confirmed for a nonpneumococcal pathogen that were 
also pneumococcal PCR positive and had high load.
The gain in specificity in using high pneumococcal load in 
blood compared to any positivity was at little cost to sensitivity 
as all but 1 PCR-positive MCPP case had high load. However, 
overall the sensitivity was poor (62.5%). This may be due in 
part to such small specimen volumes being tested, increasing 
the likelihood of cases with low bacterial counts in blood to 
be missed. Repeat testing may improve the sensitivity of PCR 
to detect cases with pneumococcus in the blood, but because 
these cases are more likely to be the cases with low bacterial 
load, repeat testing may not improve the sensitivity of detecting 
high load.
Two small studies evaluated pneumococcal bacteremia in 
nonhospitalized controls as measured by culture in organisms 
per milliliter; they compared blood pneumococcal culture 
load in pneumonia cases compared to controls with RTI, oti-
tis media, or fever without focus of infection [5, 7]. One study 
found that pneumococcal culture load was similar between 
dPercentages in the “Total” row represent column percentages. In all subsequent rows, the number and percentage represent children in the corresponding case/control group and whole-
blood pneumococcal load category who had the characteristic.
eTest for trend from Cochran-Armitage in binomial proportions: The first P value listed is across all 4 whole-blood PCR quantity categories and the second P value is across the last 3 PCR 
quantity categories for which pneumococcus was detected in the blood.
fFour sites had introduced PCV prior to start of enrollment: Kenya, The Gambia, Mali, and South Africa. Results restricted to PCV-using sites only are shown in Supplementary Table 4A, where 
there was no longer an association observed among controls.
gPrior antibiotic use defined as serum bioassay positive (cases and controls), antibiotic administration at the referral facility, or antibiotic administration prior to whole-blood specimen col-
lection at the study facility (cases only).
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pneumonia cases and controls, with 1 of 4 (25%) pneumonia 
cases having ≥10 organisms/mL compared with 5 of 25 (20%) 
controls (investigators observed similar findings for H. influen-
zae), whereas the other found high load in the single pneumo-
nia case compared to 1 of 19 controls.
There are few studies that describe the factors associated with 
pneumococcal PCR load in blood. Only 2 studies in children 
were found [20, 21], 1 of which evaluated a different gene target, 
pneumolysin (ply), in only 11 blood culture–negative Malawian 
children with CXR+ pneumonia [20].The distribution of load in 
the Malawian study (median, 0.34 × 103 copies/mL) was similar 
to that in comparable PERCH cases (median, 0.3 × 103 copies/
mL), whereas the distribution in the other South African study 
(median in children, approximately 2.8 log10 [0.63 × 10
3] copies/
mL) was twice as high as in PERCH. Both studies observed 
higher load in HIV-infected children, in contrast to PERCH, 
which found that load did not differ by HIV status; however, the 
Malawian results were not statistically significant and included 
meningitis cases, which drove much of the difference between 
HIV-positive and HIV-negative cases, and the evaluation of 
HIV in the South African study included nonsevere pneumonia 
cases and adults, unlike PERCH. PERCH also had relatively few 
HIV-infected cases relative to the South African study.
Three studies, all in adults, evaluated the association 
between pneumococcal load in blood by PCR using the lytA 
target and pneumococcal blood culture–positive pneumo-
nia, and all observed higher pneumococcal blood load by 
PCR among blood culture–positive patients compared with 
Table 3. Percentage With Pneumococcal Whole-Blood Polymerase Chain Reaction (PCR) Load ≥2.2 Log10 Copies/mL by Nasopharyngeal/Oropharyngeal 
PCR Load >6.9 Log10 Copies/mL
Characteristic




Nonpneumococcal Cased All Controls
Total 
No.e
















WB PCR ≥2.2 Log10 
Copies/mL, No. (%)
Overall 56 35 (62.5) 3832 166 (4.3) 1745 91 (5.2) 107 10 (9.3) 4987 154 (3.1)
Pneumococcal NP/OP PCR load >6.9 log10 copies/mL
 All sites P = .07 P < .01 P < .01 P = .42 P = .12
  Yes 36 26 (72.2) 457 37 (8.1) 231 25 (10.8) 27 3 (11.1) 392 17 (4.3)
  No 18 8 (44.4) 3306 127 (3.8) 1481 65 (4.4) 77 6 (7.8) 4490 135 (3.0)
 Kenya … P = .18 P = .09 P > .99 P = .45
  Yes 0 0 (0) 26 1 (3.8) 10 1 (10.0) 3 1 (33.3) 14 1 (7.1)
  No 4 3 (75.0) 529 12 (2.3) 229 7 (3.1) 3 1 (33.3) 735 30 (4.1)
 The Gambia P = .23 P > .99 P > .99 P = .51 P > .99
  Yes 10 4 (40.0) 84 4 (4.8) 42 2 (4.8) 4 0 (0.0) 49 2 (4.1)
  No 5 0 (0.0) 474 26 (5.5) 201 10 (5.0) 10 3 (30.0) 532 27 (5.1)
 Mali P = .52 P = .47 P = .27 P = .46 P > .99
  Yes 21 17 (81.0) 140 13 (9.3) 54 7 (13.0) 12 1 (8.3) 112 4 (3.6)
  No 3 2 (66.7) 476 34 (7.1) 174 13 (7.5) 14 0 (0.0) 602 21 (3.5)
 Zambia P = .40 P = .71 P = .23 P > .99 P = .29
  Yes 3 3 (100) 41 1 (2.4) 23 0 (0.0) 1 0 (0.0) 36 2 (5.6)
  No 3 1 (33.3) 406 23 (5.7) 179 16 (8.9) 21 2 (9.5) 508 14 (2.8)
 South Africa P > .99 P < .01 P <  .01 P = .26 P = .13
  Yes 2 2 (100) 100 17 (17.0) 70 14 (20.0) 7 1 (14.3) 94 8 (8.5)
  No 3 2 (66.7) 781 31 (4.0) 428 19 (4.4) 20 0 (0.0) 864 40 (4.6)
 Thailand … … … … P > .99
  Yes 0 0 (0) 3 0 (0.0) 2 0 (0.0) 0 0 (0) 8 0 (0.0)
  No 0 0 (0) 213 0 (0.0) 94 0 (0.0) 6 0 (0.0) 606 3 (0.5)
 Bangladesh … P = .24 P = .15 … …
  Yes 0 0 (0) 63 1 (1.6) 30 1 (3.3) 0 0 (0) 79 0 (0.0)
  No 0 0 (0) 427 1 (0.2) 176 0 (0.0) 3 0 (0.0) 643 0 (0.0)
All P values obtained from Fisher exact or χ2 test.
Abbreviations: CXR, chest radiograph; MCPP, microbiologically confirmed pneumococcal pneumonia; NP/OP, nasopharyngeal/oropharyngeal; PCR, polymerase chain reaction; WB, whole 
blood.
aMCPP defined as isolation of pneumococcus from blood culture, culture or PCR of lung aspirate or pleural fluid, or BinaxNOW antigen detection on pleural fluid.
bNonconfirmed cases defined as cases without isolation of bacteria from culture of blood, lung aspirate or pleural fluid, or PCR of lung aspirate or pleural fluid.
cCXR positive (CXR+) defined as radiographic evidence of pneumonia (consolidation and/or other infiltrates).
dConfirmed nonpneumococcal case defined as a case with any nonpneumococcal bacterial pathogen detected by blood culture, by lung aspirate culture or PCR, or by pleural fluid culture 
or PCR.
eSome children who were pneumococcal WB above the threshold were missing NP/OP pneumococcal results; these children are captured in the “Overall” row but excluded from subse-
quent rows.
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blood culture–negative patients [4, 22, 23]. The PERCH study 
results support these findings; among blood pneumococcal 
PCR-positive pneumonia cases, 29 of 30 (96.7%) that were 
blood culture positive had high load compared with 166 
of 242 (68.6%) that were blood culture negative (P  <  .01). 
However, as stated above, these findings are not specific to 
pneumococcal pneumonia, as 154 of 273 (56.4%) pneumo-
coccal PCR-positive community controls had high load, as 
did 10 of 12 (83.3%) cases confirmed for a nonpneumococ-
cal pathogen, although the latter could indicate coinfection. 
A finding of high blood pneumococcal load or viable organ-
isms in the blood may be an indication of more advanced or 
severe disease, as all of the above cited studies that evaluated 
disease severity found higher load among the most severe 
cases as assessed by pneumonia severity index risk class, 
intensive care unit admission, mental status, or mortality [4, 
20–23]. Studies that evaluated pneumococcus by syndrome 
type (ie, meningitis vs pneumonia) as a measure of severity 
found higher load among meningitis compared with pneu-
monia cases [5–7]. The PERCH study also observed higher 
pneumococcal load in children who died (P  =  .05), despite 
the fact that high load was not associated with other indi-
cations of severity, such as low oxygen saturation or pneu-
monia danger signs, perhaps because all children enrolled 
in PERCH had severe or very severe pneumonia by design. 
Additionally, children with WHO-defined very severe pneu-
monia syndrome enrolled in PERCH may have been suffering 
from illness caused by organisms other than pneumococcus.
We were only able to assess the value of blood pneumo-
coccal load in the diagnosis of pneumococcal pneumonia at 
the African sites since so few cases and controls had posi-
tive blood pneumococcal PCR at the Asian sites. However, 
the load distributions of the 8 cases and 11 controls at the 
Asian sites with positive blood pneumococcal PCR detected 
overlapped, as was observed at the African sites. The PERCH 
study highlights this regional difference in positivity and the 
need for further study in Asia to interrogate the association 
of pneumococcal NP/OP and blood densities in cases and 
controls.
Our finding that some of the community controls had high 
pneumococcal loads in blood is intriguing. It is possible that 
this might indicate early signs of or increased risk of developing 
disease in some of these children. Because we did not follow 
controls longitudinally, we could not determine if any went on 
to become severely ill. However, we did monitor whether cases 
enrolled in PERCH had previously been enrolled as a control, 
and none of the controls with high load were the ones we know 
of that later became a case. We also did not find that children 
with RTI were more likely than well controls to have high pneu-
mococcal blood load, which would have been expected if high 
load indicated early disease.
It was surprising to find that a greater proportion of cases 
confirmed for a nonpneumococcal pathogen had high pneu-
mococcal PCR load compared with cases not confirmed for any 
pathogen (9.3% vs 4.3%; P = .03) and that, among pneumococcal 
PCR-positive cases, the proportion with high load was similar 
Figure 3. Association between pneumococcal polymerase chain reaction (PCR) load (log10 copies/mL) in nasopharyngeal/oropharyngeal (NP/OP) and whole-blood (WB) 
specimens among cases without evidence of prior antibiotic exposure (Abx), by microbiologically confirmed pneumococcal pneumonia (MCPP) status. PCR load (density) in 
NP/OP specimens >6.9 log10 copies/mL (horizontal line) demarks the optimal colonization load (density) threshold for discriminating MCPP cases from all controls [13]. The 
shaded area to the right denotes specimens with WB pneumococcal PCR load ≥2.2 log10 copies/mL. MCPP was defined as pneumococcus isolated from culture of blood, lung 
aspirate, pleural fluid, PCR of lung aspirate or pleural fluid, or detection of Streptococcus pneumoniae antigen in pleural fluid on BinaxNOW. Nonconfirmed cases were defined 
as cases without isolation of bacteria from culture of blood, lung aspirate or pleural fluid, or PCR of lung aspirate or pleural fluid. Prior antibiotic exposure was defined as 
serum bioassay positive, antibiotic administration at the referral facility, or antibiotic administration prior to WB specimen collection at the study facility.
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to that in MCPP cases. Perhaps some had true dual infection 
with >1 pathogen causing their pneumonia. It is also possible 
that pneumococcus colonizing the nasopharynx entered the 
bloodstream because of reduced immune protection or some 
other mechanism related to the pneumonia caused by the other 
nonpneumococcal pathogen.
A major limitation of any blood test in the attribution of 
pneumococcus as the etiologic cause of a pneumonia epi-
sode is the fact that existing methodologies can only identify 
pneumococcal cases in which pneumococci have entered the 
bloodstream, and will miss those where bacteremia is absent or 
transient. Therefore, other measurements such as high load in 
the nasopharynx may help identify the pneumococcal cases in 
whom bacteremia is not detected.
The associations of pneumococcal load in blood with 
MCPP case status, blood culture positivity, and severity are 
intuitive. However, blood pneumococcal load by itself can-
not be used for diagnosing pneumococcal pneumonia in 
individual children 1–59  months of age. This signals that 
the determinants of pneumococcal load in blood by PCR are 
complex and incompletely understood. Despite this, pneu-
mococcal load in blood may be informative in attributing 
the burden of disease caused by pneumococcus in epidemi-
ological studies.
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